Matthew Luchini
Stock Analyst at BMO Capital
(2.08)
# 2,888
Out of 4,944 analysts
34
Total ratings
44.44%
Success rate
6.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $5.09 | +489.39% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $2.97 | +6,297.31% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $26.58 | +159.59% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $8.62 | +1,106.50% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $2.33 | +2,260.52% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $7.09 | +1,324.54% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $561.55 | +12.19% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $373.46 | -66.80% | 2 | Nov 6, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $120.14 | -46.73% | 2 | Oct 29, 2020 | |
| VKTX Viking Therapeutics | Initiates: Outperform | $14 | $41.27 | -66.08% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.17 | +5,028.21% | 2 | Dec 3, 2019 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $5.09
Upside: +489.39%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $2.97
Upside: +6,297.31%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $26.58
Upside: +159.59%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $8.62
Upside: +1,106.50%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $2.33
Upside: +2,260.52%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $7.09
Upside: +1,324.54%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $561.55
Upside: +12.19%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $373.46
Upside: -66.80%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $120.14
Upside: -46.73%
Viking Therapeutics
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $41.27
Upside: -66.08%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.17
Upside: +5,028.21%